KEY TAKEAWAYS French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

A Cambridge company researching treatments for blood cancers is ceasing operations and will lay off more than 150 people, ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

Epidermolysis bullosa is a rare and severe skin disease where patients have fragile skin that blisters and tears. A Mt.

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

FDA says a ‘statistically significant’ benefit on overall survival is required to approve the ivonescimab antibody.

New Biotech Communicators Network designed to strengthen community and relationships among biotech communicators.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

PARIS] Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare ...